INNsight Newsletter - June Edition
Welcome to the June edition of INNsight Newsletter, where we share with you the latest news and insights from?IQVIA Global Market Insights.?
This month's thought leadership includes:
Understanding the surge in new product launches in China’s Pharma Market
The article outlines China’s updated drug approval process post-2015 reforms, noting a median NDA approval time reduction to 15.4 months. It emphasizes the effectiveness of the Priority Review and Urgently Needed Overseas Drugs pathways in enhancing market access and explains the strategic use of launch lag analysis in Forecast Link. Read more
领英推荐
M&A deal values soar in Q1 2024
In Q1 2024, the life sciences sector experienced a 10% decrease in M&A deals compared to Q1 2023, with 84 deals signed. However, the median deal value saw a 118% increase, excluding the outlier Pfizer/Seagen deal from Q1 2023, reflecting a shift towards high-value acquisitions of de-risked assets. Big pharma made a return to M&A dealmaking in Q1 2024, with 15% of deals involving a top 20 biopharma company. Focus remained on oncology and endocrine/metabolic disorders, with a preference for bolt-on acquisitions with structured payments to manage risks.?Read more
Global oncology trends 2024: Outlook to 2028
This report profiles the latest data on cancer incidence and survival, the current state of research and development activity, including key mechanisms, targets and cancer types being investigated. Clinical development productivity and the use of novel mechanisms in cancer treatment are key areas of focus. Expectations for oncology spending over the next five years indicate significant changes in treatment trends and financial dynamics. Read more
To learn about IQVIA Global Market Insights' solutions and how we can support your business, follow this link.